Initiation of antiretroviral therapy in hiv infection: A review of interstudy consistencies

Journal of Acquired Immune Deficiency Syndromes

Volumn 7, Issue , 1994, Pages S12-S23

  Volberding, Paul A ^a   Graham, Neil M H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiretroviral therapy; CD4+ cell count; Clinical trials; Human immunodeficiency virus

Indexed keywords

ANTIVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; PRIORITY JOURNAL;

COHORT STUDIES; CONTROLLED CLINICAL TRIALS; DOUBLE-BLIND METHOD; HIV INFECTIONS; HUMAN; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; ZIDOVUDINE;

EID: 0028150834     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Fischi MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317: 185-91.
2. Fischl MA, Richman DD, Causey DM, et al. Prolonged zi-dovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA 1989;262:2405-10.
3. Richman DD. Andrews J. Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection. Am J Med 1988:85:208-13.
4. Fischi MA, Richman DD. Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of persons with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med 1990; 112:727-37.
5. Volberding PA, Lagakos SW. Koch MA. et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990:322:941-9.
6. Volberding P, Lagakos SW, Grimes JM, Stein DS. and the ACTG 019 Study Team. The effect of disease stage on the duration of zidovudine’s effect. Presented at the IX International Conference on AIDS. Berlin, Germany; July, 1993: Abstract WS-B24-6.
7. Cooper DA, Gatell JM, Kroon S, et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 1993;329:297-303.
8. Fischi MA, Parker CB, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990;323:1009-14.
9. National Institutes of Health State-of-the-Art Conference Panel. State-of-the art conference on azidothymidine therapy for early HIV infection. Am J Med 1990;89:335-44.
10. Hamilton JD, Hartigan PH, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 1992;326:437-3.
11. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994,343:871-81.
12. Graham NMH. Concorde trial of immediate versus deferred zidovudine [Letter]. Lancet 1994;343:1355-6.
13. Graham NMH, Zeger SL, Park LP, et al. Effect of zidovudine and Pneumocystis carinii prophylaxis on progression of HIV-1 infection to AIDS. Lancet 1991;338:265-9.
14. Graham NMH, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med 1992;326:1037-42.
15. Graham NMH, Piantadosi S, Park LP, Phair JP, Rinaldo CR, Fahey JL. CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time. J Acquir Immune Defic Syndr 1993;6:1258-66.
16. Saah AJ, Hoover DR, He Y, Kingsley LA, Phair JP, and the Multicenter AIDS Cohort Study. Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 1994;7:287-95.
17. Longini IM, Clark WS, Karon JM. Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population-based cohort. Am J Epidemiol 1993;137:1229-40.
18. Velia S, Giuliano M, Pezzotti P, et al. Survival of zidovu-dine-treated patients with AIDS compared with that of contemporary untreated patients. JAMA 1992;267:1232-6.
19. Vella S, Giuliano M, Dally LG, et al. Long-term follow-up of zidovudine therapy in asymptomatic HIV infection: results of a multicenter cohort study. J Acquir Immune Defic Syndr 1994;7:31-8.